Wednesday, January 30, 2013

News & Events CDER Forum for International Drug Regulatory Authorities, June 2013

News & Events CDER Forum for International Drug Regulatory Authorities, June 2013

Pharmacists Have Admitted That Sterile Compounds Are Often Contaminated


As deaths continue to climb in the ongoing outbreak of fungal meningitis infections caused by contaminated pain shots, a new survey of hospital pharmacists shows that they believe it could happen again.
About 13 percent of pharmacists, pharmacy technicians and others who responded to a poll from the Institute for Safe Medication Practices said that they believed contamination had occurred in the compounded sterile drugs made by their shops last year.
Those are the same types of drugs now blamed for 45 deaths and nearly 700 infections in people who received tainted injectable steroids made by the shuttered New England Compounding Center of Framingham, Mass., according to the Centers for Disease Control and Prevention.

continue reading at:
Sterile drugs often contaminated, pharmacists admit


 


 

POSITIVE STORIES ABOUT COMPOUNDING

I continue to ask readers to submit their positive stories relating to compounded medications.  If you have such a story or know of one on the Internet that I have not already posted, please feel free to either comment or email it to me.  I would love to hear from doctors, pharmacists, veterinarians, consumers or anyone else who has a positive story to tell.

Should doctors and patients be informed when high-risk pharmacy compounded products are used?

Filed Under: Michael Cohen
POSTED: Friday, January 25, 2013, 9:34 AM
The fungal meningitis outbreak that’s been gripping the country since last fall has now affected 678 patients and caused 44 deaths. Contaminated steroid injections tied to the outbreak have led to a wake-up call about a dangerous gap in regulatory oversight of compounding pharmacies that mix some injectable medications. In an earlier blog, I noted that such compounded preparations are not approved by the FDA and pharmacies also are generally not FDA-inspected.  So there is inherent risk when a compounding pharmacy acts as a manufacturer using non-sterile drug powder. In most states, including Pennsylvania, compounding pharmacy sterile processes do not undergo intensive state inspection.
Should these conditions warrant disclosure to those prescribing and administering the medication and to patients who receive the compounded medications? Do healthcare providers even consider whether they have an ethical and legal obligation to inform end users when they dispense high risk sterile products (injectables made from non-sterile ingredients) prepared by a compounding pharmacy. To do that, doctors who inject these products need to be informed of the source. We decided to probe into pharmacy staff viewpoints about whether or not such transparency should be a part of the picture.
Results of a survey the Institute for Safe Medication Practices (ISMP) conducted in the fall were released this week and provide new insights into how hospitals have been managing the preparation and/or purchase of compounded high risk sterile products. Our survey was fielded in November and December and had 412 pharmacist and pharmacy technician respondents. Results were published in the January 24, 2013 issue of the ISMP Medication Safety Alert!®.
 
Continue reading here


Another Country Viewing Blog


Added Tanzania and Ghana

Algeria
Argentina
Australia
Austria
Azerbaijan
Bahamas
Bangladesh
Barbados
Belgium
Brazil
Bulgaria
Cayman Islands